These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3885394)

  • 81. Structure-based design of a cyclophilin-calcineurin bridging ligand.
    Alberg DG; Schreiber SL
    Science; 1993 Oct; 262(5131):248-50. PubMed ID: 8211144
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The cyclosporin-A-sensitive event in lymphocyte activation.
    Kay JE
    Ann Inst Pasteur Immunol; 1987; 138(4):622-5. PubMed ID: 3118906
    [No Abstract]   [Full Text] [Related]  

  • 83. Cyclosporin-binding sites of murine sensitive and resistant lymphoid cell lines.
    Koponen M; Loor F
    Ann Immunol (Paris); 1983; 134D(2):207-22. PubMed ID: 6607025
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cyclosporin A: recent developments in the mechanism of action and clinical application.
    Feutren G
    Curr Opin Immunol; 1989 Dec; 2(2):239-45. PubMed ID: 2696486
    [No Abstract]   [Full Text] [Related]  

  • 85. Activity of some natural and modified (fluorescent) cyclosporins on T cells.
    Koponen M; Loor F
    Ann Immunol (Paris); 1983; 134C(2):171-89. PubMed ID: 6307114
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Cyclosporin as a probe for different modes of lymphocyte activation.
    Klaus GG
    Ann Inst Pasteur Immunol; 1987; 138(4):626-8. PubMed ID: 3499915
    [No Abstract]   [Full Text] [Related]  

  • 87. Effect of cyclosporin A (CyA) on the immune response. CyA competitively inhibits the function of monocyte/macrophage-derived T-lymphocyte-activating factor(s).
    Bendtzen K; Petersen J
    Immunol Lett; 1982; 5(6):331-6. PubMed ID: 6762338
    [TBL] [Abstract][Full Text] [Related]  

  • 88. T-lymphocyte inhibition by cyclosporine. Potential mechanisms of action.
    Colombani PM; Hess AD
    Biochem Pharmacol; 1987 Nov; 36(22):3789-93. PubMed ID: 3318839
    [No Abstract]   [Full Text] [Related]  

  • 89. Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells.
    Zeevi A; Eiras G; Burckart G; Makowka L; Venkataramanan R; Wang CP; Van Thiel DH; Murase N; Starzl TE; Duquesnoy R
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):115-21. PubMed ID: 2966474
    [No Abstract]   [Full Text] [Related]  

  • 90. Artemisinin can inhibit the calmodulin-mediated activation of phosphodiesterase in comparison with Cyclosporin A.
    Noori S; Hassan ZM; Rezaei B; Rustaiyan A; Habibi Z; Fallahian F
    Int Immunopharmacol; 2008 Dec; 8(13-14):1744-7. PubMed ID: 18793755
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Analogs of cyclosporin A modified at the D-Ala8 position.
    Patchett AA; Taub D; Hensens OD; Goegelman RT; Yang L; Dumont F; Peterson L; Sigal NH
    J Antibiot (Tokyo); 1992 Jan; 45(1):94-102. PubMed ID: 1548192
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Complexity of the primary genetic response to mitogenic activation of human T cells.
    Zipfel PF; Irving SG; Kelly K; Siebenlist U
    Mol Cell Biol; 1989 Mar; 9(3):1041-8. PubMed ID: 2498643
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cytoplasmic lipid droplets as the possible eventual cellular fate of active forms of cyclosporin.
    Koponen M; Loor F
    Exp Cell Res; 1983 Dec; 149(2):499-512. PubMed ID: 6315463
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Adverse reactions and interactions of cyclosporin.
    Scott JP; Higenbottam TW
    Med Toxicol Adverse Drug Exp; 1988; 3(2):107-27. PubMed ID: 3287088
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Topical cyclosporin and T lymphocytes in keloid scars.
    Duncan JI; Thomson AW; Muir IF
    Br J Dermatol; 1991 Jan; 124(1):109. PubMed ID: 1993135
    [No Abstract]   [Full Text] [Related]  

  • 96. Cyclosporin Structure and Permeability: From A to Z and Beyond.
    Corbett KM; Ford L; Warren DB; Pouton CW; Chalmers DK
    J Med Chem; 2021 Sep; 64(18):13131-13151. PubMed ID: 34478303
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells.
    Ma W; Mishra S; Gee K; Mishra JP; Nandan D; Reiner NE; Angel JB; Kumar A
    J Biol Chem; 2012 Jan; 287(1):804. PubMed ID: 22319783
    [No Abstract]   [Full Text] [Related]  

  • 98. Pillars Article: Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation.
    Emmel EA; Verweij CL; Durand DB; Higgins KM; Lacy E; Crabtree GR
    J Immunol; 2018 Dec; 201(11):3149-3152. PubMed ID: 30455370
    [No Abstract]   [Full Text] [Related]  

  • 99. Proteomic analysis of T cell activation in the presence of cyclosporin A: immunosuppressor and activator removal induces de novo protein synthesis.
    Truffa-Bachi P; Lefkovits I; Rudolf Frey J
    Mol Immunol; 2000 Apr; 37(5):261. PubMed ID: 10930633
    [No Abstract]   [Full Text] [Related]  

  • 100. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19.
    Liu C; von Brunn A; Zhu D
    Med Drug Discov; 2020 Sep; 7():100056. PubMed ID: 32835213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.